Mesoblast Limited (ASX:MSB – Get Free Report) insider Gregory George acquired 74,621 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were bought at an average cost of A$12.88 ($8.20) per share, with a total value of A$961,118.48 ($612,177.38).
Gregory George also recently made the following trade(s):
- On Monday, March 3rd, Gregory George purchased 5,034,129 shares of Mesoblast stock. The shares were purchased at an average price of A$2.95 ($1.88) per share, with a total value of A$14,830,544.03 ($9,446,206.39).
Mesoblast Price Performance
The firm has a market capitalization of $2.32 billion, a PE ratio of -23.29, a price-to-earnings-growth ratio of 9.56 and a beta of 2.38. The company has a current ratio of 1.18, a quick ratio of 1.82 and a debt-to-equity ratio of 24.76.
Mesoblast Company Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
- Five stocks we like better than Mesoblast
- Basic Materials Stocks Investing
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Stock Dividend Cuts Happen Are You Ready?
- 3 Must-Own Stocks to Build Wealth This Decade
- Business Services Stocks Investing
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
